Abbonarsi

The unicompartmental knee implant UniSpacer™: Ten-year outcomes after treatment for medial tibio-femoral osteoarthritis - 27/04/21

Doi : 10.1016/j.otsr.2021.102873 
Matthieu Courtine a, , Ludovic Labattut a, Pierre Martz a, b, Emmanuel Baulot a, b
a Service de chirurgie orthopédique et traumatologique, CHU de Dijon Bourgogne, 21000 Dijon, France 
b Inserm UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR des Sciences de Santé, 21000 Dijon, France 

Corresponding author at: Service de chirurgie orthopédique et traumatologique, CHU Dijon, 14 rue Paul Gaffarel, 21079 Dijon Cedex, France.Service de chirurgie orthopédique et traumatologique, CHU Dijon14 rue Paul GaffarelDijon Cedex21079France

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

UniSpacer™ type implants were part of the therapeutic armamentarium for medial tibio-femoral osteoarthritis before they were taken off the market in 2011. UniSpacer™ is a mobile interpositional self-centring implant that replicates the shape of the meniscus. It requires no bone cuts or component fixation. The objective of this follow-up note is to provide data on the 10-year outcomes in a cohort investigated previously in a study published in 2011. This study provides a re-evaluation of implant survival 5 years after the first analysis, as well as information on patient satisfaction and functional outcomes.

Hypothesis

UniSpacer™ survival remains stable after 5 additional years and provides satisfactory functional outcomes.

Material and methods

We included the same patients operated on from 2003 to 2009, namely, with 17 UniSpacer™ implants in 16 patients. The operative technique was the same in all patients. At last follow-up, the patients attended a visit designed specifically to allow a clinical evaluation (IKS score, revision, forgotten implant) and new radiographic imaging of the treated knee.

Results

Mean follow-up of this retrospective study of a prospective database was 118±25 months. Of the 17 implants, 9 (53%), in 8 patients, were still in place. Six (37.5%) patients underwent early revision arthroplasty (between 6 months and 4 years). One patient was lost to follow-up and another had died. The mean global IKS knee score was 76±15 and the mean IKS function score was 80±25. The global IKS score at last follow-up was 157±39. Mean range of flexion was 119±20°. Of the 8 patients (9 implants) who still had their implants at last follow-up, 5 (56%) reported forgetting their implant. No revisions were performed between 4 and 10 years of follow-up.

Discussion

The ten-year survival was limited (53%). Clinical outcomes were satisfactory in the patients who still had their implants. The low cost and simplicity of insertion may make this implant a reasonable alternative for patients with contraindications to very major surgery.

Level of evidence

IV.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Tibio-femoral osteoarthritis, UniSpacer™, Knee osteoarthritis


Mappa


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 107 - N° 3

Articolo 102873- maggio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Disappointing Relationship between Functional Performance and Patient Satisfaction of UKA Patients: A Cross Sectional Study
  • Kwaku Baryeh, Cedric Maillot, Advaith Gummaraju, Charles Rivière
| Articolo seguente Articolo seguente
  • Absence of signature inflammatory markers in synovial fluid for total knee arthroplasties revised for arthrofibrosis
  • Christopher G. Salib, Nicolas Reina, Andre J. van Wijnen, Arlen D. Hanssen, Daniel J. Berry, Matthew P. Abdel

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.